



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 31/02	A1	(11) International Publication Number: WO 89/10118 (43) International Publication Date: 2 November 1989 (02.11.89)
(21) International Application Number: PCT/US89/01388 (22) International Filing Date: 10 April 1989 (10.04.89) (30) Priority data: 187,854 29 April 1988 (29.04.88) US (71) Applicant: HEMAGEN/PFC [US/US]; Four Embarcad- ero Center, Suite 3320, San Francisco, CA 94111 (US). (72) Inventors: KAUFMAN, Robert, J. ; 8129 Stanford Ave- nue, University City, MO 63130 (US). RICHARD, Tho- mas, J. ; 8607 Rowland, University City, MO 63132 (US). (74) Agent: HALEY, James, F., Jr.; Fish & Neave, 875 Third Avenue, 29th Floor, New York, NY 10022-6250 (US).		(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK, FI, FR (European patent), GA (OAPI pa- tent), GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: IMPROVED EMULSIONS OF HIGHLY FLUORINATED ORGANIC COMPOUNDS (57) Abstract Improved emulsions of highly fluorinated organic compounds. The emulsions comprise a highly fluorinated organic com- pound, an oil, that is not substantially surface active and not significantly water soluble, and a surfactant. They are characterized by a well-defined relationship in the relative amounts of the three components.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria
AU Australia
BB Barbados
BE Belgium
BG Bulgaria
BJ Benin
BR Brazil
CF Central African Republic
CG Congo
CH Switzerland
CM Cameroon
DE Germany, Federal Republic of
DK Denmark
FI Finland

FR France
GA Gabon
GB United Kingdom
HU Hungary
IT Italy
JP Japan
KP Democratic People's Republic
of Korea
KR Republic of Korea
LI Liechtenstein
LK Sri Lanka
LU Luxembourg
MC Monaco
MG Madagascar

ML Mali
MR Mauritania
MW Malawi
NL Netherlands
NO Norway
RO Romania
SD Sudan
SE Sweden
SN Senegal
SU Soviet Union
TD Chad
TG Togo
US United States of America

-1-

IMPROVED EMULSIONS OF
HIGHLY FLUORINATED ORGANIC COMPOUNDS

TECHNICAL FIELD OF THE INVENTION

This invention relates to improved emulsions
5 of highly fluorinated organic compounds and to
processes of making and using them. More particu-
larly, this invention relates to fluorocarbon-
containing emulsions having acceptable particle size
distributions both after sterilization and in the
10 presence of serum, being safe at high doses and in
total exchanges and having good shelf stability at
room temperature. These emulsions comprise a highly
fluorinated organic compound, an oil, that is not
substantially surface active and not significantly
15 soluble in water and a surfactant. The emulsions
are characterized by a well defined relationship in
the relative amounts of these three components.
Such emulsions are especially useful in compositions
for use as oxygen transport agents, "artificial
20 bloods", or red blood cell substitutes, in the treat-
ment of heart attack, stroke, and other vascular
obstructions, as adjuvants to coronary balloon angio-
plasty and cancer radiation treatment and chemotherapy
and as contrast agents for biological imaging.

-2-

BACKGROUND OF THE INVENTION

Highly fluorinated organic compounds, such as perfluorocarbon compounds ("PFC") are well known to be chemically and pharmaceutically inert. They also have the capacity of dissolving, transporting and delivering biologically and chemically significant quantities of oxygen. These properties make them potentially useful as oxygen transport agents, "artificial bloods" or red blood cell substitutes, in the treatment of heart attack, stroke and other vascular obstructions, as adjuvants to coronary angioplasty, cancer radiation treatment and chemotherapy and as contrast agents for various biological imaging modalities, such as nuclear magnetic resonance, ultrasound, x-ray and positron emission tomography.

Neat fluorocarbon liquids, however, cannot be injected into the blood stream, because their hydrophobic character makes them immiscible in the blood. As a result, they may cause vascular obstruction and death when transported into small blood vessels. Accordingly, for medical uses that require intravascular injection, such highly fluorinated organic molecules must be dispersed as physiologically acceptable, aqueous emulsions. See, e.g., L. C. Clark, Jr. et al., "Emulsions of Perfluorinated Solvents for Intravascular Gas Transport", Fed. Proc., 34(6), pp. 1468-77 (1975); K. Yokoyama et al., "A Perfluorochemical Emulsion as an Oxygen Carrier", Artif. Organs (Cleve), 8(1), pp. 34-40 (1984); and United States patents 4,110,474 and 4,187,252.

To date the medical usefulness of such emulsions of highly fluorinated organic compounds as "artificial bloods", red blood cell substitutes, oxygen transport agents or contrast agents for biological imaging has not been as successful as hoped. This results from the fact that none of the prior fluorocarbon-containing emulsions satisfies all of

-3-

requirements of a preferred "artificial blood" or oxygen transport agent.

These requirements include:

- 5 (1) Particle Size Distribution (PSD)
 Post Sterilization Less Than 400 nm

 A critical parameter for stability and safety is the PSD of the emulsion. Extensive prior art literature demonstrates that a PSD >400 nm results in excessive toxicity because the microcirculatory
10 filters large particles leading to clogged micro-circulatory vasculature and ultimately general ischemia. The particle size will also impact the rate of clearance from the circulatory system and emulsions which are not maintained in the circulatory
15 system will not be efficacious as blood substitutes. Because terminal heat sterilization of these emulsions is necessary to eliminate the possibility of sepsis before use, emulsions which exhibit a PSD >400 nm (post sterilization) are, thus, not acceptable.

- 20 (2) Serum Stability Characterized
 By A PSD <400 nm After Five Days
 In Serum Or Ionic Solutions

 Of great importance to a given emulsion formulation is stability to the serum environment.
25 A lack of serum or ionic stability results in particles that grow in vivo resulting in emboli that may clog the microvasculature and may lead to paralysis and death. In addition to the catastrophic growth that leads to death, modest in vivo particle
30 growth results in more rapid clearance from the circulatory system and hence reduced efficacy as a red blood cell substitute or oxygen transport agent. Accordingly, emulsions which exhibit a PSD >400 nm (after 5 days in serum or ionic solutions) are not
35 acceptable.

-4-

(3) Survival At High Doses

A major limitation to the use of an emulsion is the LD₅₀ or maximum safe dose. Regulatory agencies limit the use level of an emulsion based on some fraction of the LD₅₀. Emulsions which have a higher maximum allowable dose and, thus, can be used in higher, more effective dosages and in a broader range of clinical applications will be more broadly accepted by the medical community. An acceptable emulsion should have an LD₅₀ in rats of at least 16 ml/kg of the perfluorocarbon component -- the active ingredient of the emulsion.

(4) Survival In Total Exchanges

Total exchange transfusions represent the most stringent test of emulsion safety and efficacy. In a total exchange, the animal's hematocrit is reduced to 3% or less, a level which would be fatal without intervention. Simultaneously, the candidate emulsion is isovolumically infused. The animal's physiologic functions, survival, general appearance and health, and intravasculture persistence are then monitored. Emulsions which lead to a high level of survival are believed to have good safety and efficacy. An acceptable emulsion should have at least a 70% survival rate in total exchanges in rats.

(5) Shelf Stability

A key criteria for the commercial utility of an emulsion is its shelf stability. Emulsions which cannot be stored for several months at either 4°C, and more preferably 25°C, will not be useful in the field. Their shelf life will be too short with respect to the time lag between manufacturing and quarantine, shipping, and usage.

-5-

In addition to these requirements, fluoro-carbon-containing emulsions that are to be used as "artificial bloods" or "red blood cell substitutes" must deliver sufficient oxygen to the tissues of the body.

As is well known, blood oxygen is normally transported by hemoglobin, a highly specialized protein that on-loads oxygen in the lungs and off-loads oxygen in the tissues of the body. When atmospheric oxygen, which has an oxygen partial pressure (pO_2) of approximately 150 mm Hg, is breathed and is present in the alveoli of the lungs, the arterial blood pO_2 is about 100 mm Hg (because of the water vapor saturating the gas in the pulmonary alveoli, the bronchial circulation and other sources of arterio-venous shunting through the lungs). At this relatively low pO_2 all of hemoglobin's carrier sites for oxygen are almost completely saturated (97%). Thus, when the oxygen dissolved in the arterial blood plasma is in equilibrium with the hemoglobin of whole blood, 100 ml of that blood will carry about 20 ml of oxygen (20 volume percent).

When this oxygen-carrying blood moves into the capillaries where it off-loads its oxygen to the tissues, it comes into dynamic oxygen equilibrium with the oxygen present in the perivascular interstitial fluid, which on average has a pO_2 of 40 mm Hg. This difference in pO_2 level between the arterial and the venous side of the circulation permits delivery to the tissues of their normal requirement of about 5 ml of oxygen per 100 ml of whole blood (5 volume percent).

In contrast to hemoglobin which actually binds and then releases oxygen, emulsions of highly fluorinated organic compounds merely dissolve oxygen. Accordingly, the amount of oxygen delivered by a fluorocompound-containing emulsion depends on the

-6-

difference between the arterial pO_2 and the venous pO_2 , the solubility of oxygen in the fluorocarbon and the percentage (by volume) of the fluorocarbon in the emulsion:

$$\begin{aligned} 5 \quad \text{Delivery of } O_2 = & ((\text{arterial } pO_2 - \text{venous } pO_2)/760) \\ & \text{(volume \%)} \quad \times (\text{solubility of } O_2 \text{ in the fluoro-} \\ & \text{com pound}) \times (\text{percentage (by} \\ & \text{volume) of the fluorocompound in} \\ & \text{the emulsion}). \end{aligned}$$

10 For use as an "artificial blood" or red blood cell substitute, a fluorocompound-containing emulsion should deliver at least as much oxygen as whole blood -- 5% by volume. At the 100% O_2 breathing mixture used for up to 12 hours in critical care
15 situations, such an emulsion should, thus, contain at least about 20% by volume of the fluorocompound. E.g. (using the equation above):

$$\text{desired } O_2 \text{ delivery} = 5\% \text{ (by volume)}$$

$$\text{arterial } pO_2 = 600 \text{ mm Hg (100\% } O_2) *$$

$$20 \quad \text{venous } pO_2 = 40 \text{ mm Hg}$$

$$\begin{aligned} \text{solubility of } O_2 \text{ in fluorocompound} &= 33\% \\ & \text{(by volume)**} \end{aligned}$$

$$\begin{aligned} \text{percentage (by volume)} \\ \text{of fluorocarbon required} &= x \end{aligned}$$

25

* The approximate conventionally assumed arterial pO_2 of a healthy 20 year old at 100% O_2 .

30 ** At 37°C, most perfluorocarbon-containing compounds have similar Bunsen oxygen solubility coefficients. These range between about 0.32 to 0.35, i.e., the solubility of O_2 in them is between about 32 to 35% (by volume).

-7-

$$x = \frac{0.05}{\frac{(600-40)}{760} (0.33)} = 20.5\%$$

5 At the 40% to 80% O₂ breathing mixture tolerated for longer times than 12 hours in hospital settings, such emulsion should contain from about 25% to about 60% by volume of the fluorocarbon, and most preferably from 30% to 55% by volume.

10 It is clear from the foregoing that without relatively high PFC contents, perfluorocarbon emulsions will not be capable of delivering the quantities of oxygen that are available from whole blood. Compounding the oxygen delivery shortcomings
15 of low % (by volume) PFC emulsions are two additional factors critical to the medical use of perfluorocarbon emulsions. The first is the need for high oxygen delivery per unit volume of fluid administered. There is a limit to the volume of fluid that can be
20 delivered to a patient, especially if the heart or kidneys are suspected to be compromised. The second additional shortcoming of low % (by volume) PFC emulsions is that in high volume transfusions it is usually necessary to mix the infused emulsion with
25 other solutions needed to support the ionic and oncotic needs of the patient. Therefore, dilution of low % PFC emulsions with "annex" solutions containing salts and suitable plasma expanders serves to dilute the already low oxygen delivery capacity of
30 these formulations.

 Illustrative of the deficiencies of prior fluorocarbon-containing emulsions is "Fluosol DA 20%", the only fluorocarbon emulsion to reach clinical testing as an "artificial blood". It is an about
35 10% (by volume) emulsion of two fluorocarbons -- perfluorodecalin and perfluorotripropylamine -- in a mixture of two surfactants -- egg yolk phospholipid and Pluronic F-68. It is not stable in the liquid

-8-

state and must be stored frozen (Yokoyama et al.,
supra). Furthermore, the required presence of the
perfluorotripropylamine in this emulsion, to help
"stabilize" it, virtually eliminates the emulsion's
5 medical usefulness (as an artificial blood or oxygen
transport agent) because the half-life of the per-
fluorotripropylamine in the liver and the other body
tissues is longer than desirable (see, e.g.,
K. Yokoyama et al., supra). Finally, because this
10 emulsion contains only about 10% fluorocarbon by
volume, it is much less therapeutically effective as
an "artificial blood" than desired because of its
low oxygen delivery capacity -- about 2.4% O₂ at
100% inspired oxygen (see, e.g., "Fluosol-DA As A
15 Red Cell Substitute In Acute Anemia", N.E. Jour. Med.,
314, pp. 1653-66 (1986)). This is substantially less
than the 5 volume % oxygen which must be delivered
to sustain healthy physiologic function.

Also illustrative of these deficiencies
20 are the three fluorocarbon emulsions referred to
in Jeppsson et al., "Particle Size Distribution Of
A Fluorochemical Emulsion", in HS Symposium Research
on Perfluorochemicals in Medicine and Biology,
Huddinge, Sweden, April 28-29, 1977, Karolinska
25 Institute Research Center, Proceedings, Novakova,
et al., ed., pp. 108-113 (1978). These emulsions
contain about 15% (by volume) fluorocarbon -- too
little to be useful as an "artificial blood" or "red
blood cell substitute" -- a use, in fact, never even
30 suggested by Jeppsson.

One attempt to remedy the problems of these
prior art fluorocarbon-containing emulsions is
described in Shaw-Clark European patent application
231,091. The emulsions of that application are
35 characterized by high fluorocarbon contents and good
stability at room temperature and after sterilization.
They comprise an oil that is not substantially,

-9-

surface active and not significantly soluble in water, a surfactant and a highly fluorinated organic compound. Although a vast improvement over prior emulsions, the genus of Shaw-Clark emulsions include
5 some that do not satisfy all of the other requirements described above for emulsions preferred for use as "artificial bloods", oxygen transport agents, or contrast agents for biological imaging.

Jeppsson (supra) also refers to oil, surfactant and fluorocarbon-containing emulsions. See,
10 e.g., Jeppsson, supra, and European patent applications 220,152 and 220,153. Jeppsson does not suggest that its emulsions permit the preferred higher concentrations of perfluorocarbons needed for "artificial
15 bloods", oxygen transport agents or contrast agents for biological imaging. Nor does Jeppsson suggest that its emulsions satisfy the other requirements of preferred emulsions for use in these applications. In fact, the Jeppsson emulsions include many that do
20 not satisfy all of these other requirements of the preferred emulsions described above.

SUMMARY OF THE INVENTION

This invention solves the problems referred to above. It provides for the first time emulsions
25 of highly fluorinated organic compounds that satisfy all of the requirements of the preferred emulsions described above.

The emulsions of this invention are characterized by (1) a particle size distribution after
30 sterilization of less than about 400 nm, and preferably less than about 300 nm; (2) a serum stability characterized by a particle size distribution of less than 400 nm, and preferably less than 300 nm, after five days in serum or ionic solutions; (3) an
35 LD₅₀ in rats of at least 16 ml/kg of the fluorocarbon component of the emulsion; (4) an at least 70% sur-

-10-

vival in total exchange in rats and (5) a shelf stability of at least several months at 4°C, and preferably at 25°C.

5 The improved emulsions of this invention
comprise at least one highly fluorinated organic
compound; an oil that is not substantially surface
active and not significantly soluble in water; and a
surfactant. More importantly, the emulsions of this
invention are characterized by specific and defined
10 relationships in the relative amounts of those three
components. The fluorocarbon component is present
in the emulsion in an amount between about 10% and
about 60% by volume. The amounts of the surfactant
and the oil are dependent on the volume percent of
15 fluorocarbon and are defined by the volume depicted
in Figure 1 and by the surfaces that define that
volume.

This invention also includes methods of
making these improved emulsions and methods and
20 compositions of using them as oxygen transport agents,
"artificial bloods" or red blood cell substitutes,
and contrast agents for biological imaging, and in
other medical compositions and applications known in
the art.

25 DESCRIPTION OF THE DRAWINGS

Figure 1 is a three dimensional diagram --
w/w % oil/fluorocarbon, w/w % surfactant/fluorocarbon,
and vol % fluorocarbon-containing compound -- of the
improved emulsions of this invention. The volume
30 depicted in Figure 1 and the surfaces defining it
describe the improved emulsions of this invention.
The filled-in circles in Figure 1 represent emulsions
of this invention that satisfy all of the requirements
of the preferred emulsions described above. The
35 open circles represent emulsions that fail in one or
more of those requirements.

-11-

DETAILED DESCRIPTION OF THE INVENTION

The emulsions of this invention comprise at least one highly fluorinated organic compound; an oil that is not substantially surface active and not significantly soluble in water; and a surfactant.

The emulsions of this invention are stable at room temperature for long periods of time -- at least several months. They are stable to agitation and to mixing with various physiological additives, including, but not limited to, saline, Tyrode solution, lactated Ringer's solution, serum and serum products. They exhibit substantially no phase separation and substantially no change in particle size or droplet distribution during storage. Moreover, they permit the use of highly fluorinated organic compounds that exhibit acceptably rapid excretion times from the liver and other body tissues. And they permit the use of high concentrations of fluorocarbons, thereby producing the high oxygen delivery capacity emulsions required for use as therapeutically effective blood substitutes, oxygen transport agents and contrast agents for biological imaging. Because of their stability, they retain the above-mentioned properties even after sterilization in a conventional laboratory autoclave at 121°C for fifteen minutes.

Among the highly fluorinated organic compounds that are useful in the emulsions and processes of this invention are those previously said to be useful as oxygen transport agents, "artificial bloods" or red cell substitutes, and contrast agents for biological imaging. These include perfluorocarbons, e.g., perfluorodecalin, perfluoroindane, perfluorotrimethylbicyclo[3.3.1]-nonane, perfluoromethyladamantane, perfluorodimethyladamantane, and perfluoro-2,2,4,4-tetramethylpentane; 9-12 C perfluoroamines, e.g., perfluorotripropylamine, perfluorotributylamine, perfluoro-1-azatricyclic

-12-

amines; bromo- or iodo- substituted fluorocarbons; and F-4-methyloctahydroquinolidizine and perfluoroethers. Such compounds are described, for example, in United States patents 3,962,439, 3,493,581, 5 4,110,474, 4,186,253, 4,187,252, 4,252,827, 4,423,077, 4,443,480, 4,534,978 and 4,542,147, European patent applications 80710 and 158,996, British patent specification 1,549,038, and German Offen. 2,650,586. Of course, it should be understood that mixtures of any 10 of these highly fluorinated organic compounds may also be used in the emulsions and processes of this invention.

Preferably, the emulsions of this invention contain one or more of a perfluorocarbon and more 15 preferably a perfluorocarbon selected from the group consisting of perfluorodecalin, perfluoromethyladamantane, perfluorodimethyladamantane, perfluorooctylbromide, perfluoro-4-methyloctahydroquinolidizine, perfluoro-N-methyldecahydroquinoline, 20 F-methyl-1-oxa-decalin, perfluoro-bicyclo[5.3.0]-decane, perfluorooctahydroquinolidizine, perfluoro-5,6-dihydro-5-decene, and perfluoro-4,5-dihydro-4-octene. Most preferably, the perfluorocarbon is perfluorodecalin or perfluorooctylbromide. For use 25 as a contrast agent for biological imaging, perfluorooctylbromide is the preferred highly fluorinated organic compound according to this invention.

While the highly fluorinated organic compounds, or mixture of such compounds, may comprise 30 from about 10% to about 60% (by volume) of the emulsions, the preferred emulsions of this invention employ concentrations of at least about 20% to about 60% (by volume) of the highly fluorinated organic compound. More preferably, the emulsions of this 35 invention comprise from about 30% to about 55% (by volume) fluorocarbon. Most preferably, the emulsions contain 40% by volume.

-13-

Among the not substantially surface active and not significantly water soluble oils that are useful in the emulsions and processes of this invention are liquid fatty oils, hydrocarbons, waxes, such as monoesters of a fatty acid and a monohydroxy alcohol, long chain ethers, diglycerides, silicone oils and nitriles. These include, for example, palmitoyl oleate, octyl nitrile, dodecyl nitrile, soybean oil, safflower oil, hexadecane, diglycerides having a C_{12} - C_{18} carbon chain, and mineral oil. As with the fluoro-containing component, these oils may be used singly or in various combinations in the emulsions and processes of this invention.

When the emulsions of this invention are to be used medically, the oil or combination of oils must, of course, be physiologically acceptable. For example, when our emulsions are to be used as "artificial bloods" or therapeutically as oxygen transport agents or contrast agents, we preferably use physiologically acceptable liquid fatty oils, such as soybean and safflower oils.

Among the surfactants useful in the emulsions of this invention are any of the known anionic, cationic, nonionic and zwitterionic surfactants. These include, for example, anionic surfactants such as alkyl or aryl sulfates, sulfonates, carboxylates or phosphates, cationic surfactants such as mono-, di-, tri-, and tetraalkyl or aryl ammonium salts, nonionic surfactants, such as alkyl or aryl compounds, whose hydrophilic moiety consists of polyoxyethylene chains, sugar molecules, polyalcohol derivatives or other hydrophilic groups that may be combinations of the above anionic or cationic groups, and whose hydrophobic moiety consists of any other polymer, such as polyisobutylene or polypropylene oxides. Again, combinations of these surfactants may, of course, be used in the emulsions of this invention. In addition,

-14-

mixtures of compounds, one or more of which are not surfactants, but which compounds when combined act as surfactants, may also be usefully employed as the surfactant component of the emulsions of this invention.

Again, when the emulsions of this invention are to be used in "artificial bloods" or therapeutically as oxygen transport agents or contrast agents, the surfactant, or combinations of them, must be physiologically acceptable. For example, for such uses we prefer nonionic or zwitterionic surfactants. Preferably, the surfactants used in the emulsions of this invention are one or more of the following: egg and soybean phosphatides, lecithin, and any of the series of BASF Wyandotte formulations of polyoxyethylene oxides sold under the trade name "Pluronic", especially "Pluronic F-68". Of course, many other polyethylene oxide based surfactants can be employed, but they are not typically as accessible through common channels of commerce.

In addition to the highly fluorinated organic compounds, oils, and surfactants, the emulsions of this invention contain water and may also contain, or be mixed with, other components conventionally used in "artificial bloods" or red blood cell substitutes, oxygen transport agents or contrast agents for biological imaging. These include isotonic agents, osmotic pressure controlling agents, serum extending agents and antioxidants. For example, we have successfully incorporated glycerol as a tonicity adjusting agent during the preparation of these emulsions to obtain solutions of physiologically acceptable osmolarities. The proper amounts to obtain isotonicity with respect to whole blood will be obvious to those skilled in the art. In addition, we have shown that, after preparation and heat sterilization, these emulsions may be mixed with

-15-

0.9% saline, lactated Ringer's solution, serum and serum products with no adverse affect on emulsion particle size and stability. Other adjuvants can also be used in the emulsions of this invention.

5 Among them are oncotic agents such as dextran, HES, and antioxidants.

The emulsions of this invention are characterized by a well-defined relationship in the relative amounts of the fluorocarbon, oil and surfactant components. This specific relationship or interdependence in best depicted and described by reference to Figure 1.

In Figure 1 the emulsions of this invention are defined as a volume on a three-dimensional plot of w/w% oil/fluorocarbon, w/w% surfactant/fluorocarbon, and % volume fluorocarbon. Emulsions falling within this volume, or on the surfaces defining it, are within the scope of this invention. Emulsions falling outside of this described volume and these surfaces are, correspondingly, not part of this invention.

Using Figure 1, then, one of skill in the art can readily select the range of oils and the range of surfactants useful at a particular volume % fluorocarbon to prepare the emulsions of this invention. More preferably, one of skill in the art can select a particular oil and surfactant amount within that defined range for use in preparing an emulsion of this invention.

Although Figure 1 is based on emulsions prepared with perfluorodecalin, egg yolk lecithin and safflower oil, we believe that other combinations of fluorocarbons, oils and surfactants, as described above, will display a similar interdependence of components. However, it should be understood that slightly different volumes and surfaces may define the actual interrelationship of the components of

-16-

those other emulsions. It is plainly within the skill of the art based on the teachings of this application to determine those exact volumes and surfaces without undue experimentation and without departing
5 from the scope and teachings of this invention.

In the more preferred emulsions of this invention, the fluorocarbon is perfluorodecalin, the surfactant is egg yolk lecithin, and the oil is safflower oil. In the most preferred emulsions of this
10 invention, the perfluorodecalin is present is about 40% by volume, the lecithin present in about 2.3 w/w% lecithin/PFD and the safflower oil present in about 2.6 w/w% oil/PFD.

The emulsions of this invention may be
15 prepared using any order of mixing the three components and water. However, we prefer to mix the oil first with a water dispersion of the surfactant. We then prepare the final emulsion by adding the fluorocarbon.

The mixing and emulsification of the components of the emulsions of this invention may be done with any of the mechanical homogenizers in commercial use, and do not require the use of extravagant equipment such as ultrasonic homogenizers, although such
20 equipment may be used in laboratory scale production. We prefer to use an inert atmosphere to prevent degradation of the surfactant and fatty oils and to use temperatures, preferably between about 45° and 55°C to decrease the viscosity of the material being
25 emulsified.

In order that this invention be more fully understood, we have included the following illustrative examples. These examples do not limit the foregoing disclosure of this invention.

-17-

EXAMPLESPROCEDURESPreparation Of Aqueous Lecithin Dispersion

5 Powdered, refined, egg yolk lecithin was
obtained from Kabi Vitrum and dispersed in sterile
H₂O under an inert atmosphere (N₂) using a Waring™
Blender at high speed for 2 minutes. The blended
material was transferred to a reservoir, again under
an inert atmosphere, which fed a Microfluidizer™
10 Model 110 homogenization apparatus. The material
was cycled through the homogenizer at a flow rate
of 350 ml/min, using 60 psig air pressure to drive
the pump piston, for a total of 5 minutes. The
temperature was maintained below 25°C throughout.
15 In this manner, approximately 750 g lots were pre-
pared, at concentrations ranging from 10 to 27%.
The lecithin so dispersed was collected under an
inert atmosphere and stored at 4°C. All lecithin
dispersions so prepared were used within one week
20 of their preparation.

Preparation of Emulsion

The emulsifier reservoir was first loaded
with the appropriate charge of sterile water, gly-
cerol, and lecithin dispersion described above. The
25 emulsifier was then started, and the oil was added
via a syringe pump at a flow rate of from 10-30 ml/min
directly into the inlet port of the homogenizer.
The perfluorocarbon was then added via syringe pump
at the same flow rate into the same port. The
30 temperature was maintained at 45-48°C throughout,
and the pH was maintained at 7.5-8.5 by controlled
addition of 0.29 M NaHCO₃ or other base. For a 250-ml
batch, the material was cycled through the homogenizer
at a flow rate of 300-350 ml/min for 10 minutes.
35 Proportionately longer mean residence times were

-18-

used for larger batch sizes (e.g., for a 500-ml batch, a residence time of 20 minutes was employed).

ANALYSIS

Particle Size Distribution Analysis (PSD)

- 5 Samples were analyzed according to published operating procedures on a Brookhaven BI-90 Particle Sizer. All samples were prepared in isotonic glycerol solution immediately prior to the analysis.

Serum Stability (PSD)

- 10 Samples were diluted 1:1 with a 4:1 mixture of lactated Ringer's solution and 25% human serum albumin (HSA), buffered to pH 7.2 with a phosphate buffer. Samples were incubated at 37°C for 120 hrs. before particle size distribution analysis.

15 Total Exchange

- Doubly cannulated rats (jugular vein/carotid artery) were isovolumically exchanged according to Goodin et al., "A Method For Evaluation Of Blood Substitutes In The Conscious Animal", Am. Jour. Physiol., 245, H519-523 (1983) until the hematocrit was approximately 3%. The initial PiO_2 of 0.8 was reduced daily at 0.1 increments over a 4-day span, after which the animals were returned to room air. Survival was scored at 14 days.

25 LD₅₀ Analysis

- The test emulsion (50 ml/kg of a 4:1 mixture of stem emulsion (40% by volume PFC) and annex (equivalent to 16 ml/kg of fluorocarbon component)) is infused at a rate of 1 ml/kg via the tail vein of
30 10 140-200g Sprague-Dawley rats lightly anesthetized with ether. After infusion, the animals are returned to their cage and supplied with food and water ad libitum. After 14 days the survival rate is scored.

-19-

Test emulsions of other PFC volume percents would be prepared similarly to adduce 16 ml/kg of fluorocarbon component

Shelf Stability

5 The test emulsions are stored in serum stoppered 100 ml bottles under a nitrogen atmosphere at 4°C or 25°C for at least three months. After storage, the samples are tested for particle size distribution (laser light scattering), pH, and visual
10 quality (color, creaming, etc.).

SPECIFIC EMULSIONS

Forty-seven different emulsions were prepared in duplicate by the methods outlined in the procedures section. Each emulsion contained per-
15 fluorodecalin, safflower oil and egg yolk lecithin. The actual concentrations of the components of these emulsions are described in Table I. The emulsions were then analyzed as above. The results are reported in Table II and plotted in Figure 1 -- open circle
20 for those that failed one or more requirements and filled-in circle for those that satisfied all requirements.

-20-

TABLE I

	<u>Ex. No.</u>	<u>Lec/PFD (w/w%)</u>	<u>Saf/PFD (w/w%)</u>	<u>PFD% (v/v)</u>
	1	0.66%	2.6%	30.0%
5	2	1.15%	13.0%	30.0%
	3	2.08%	17.4%	30.0%
	4	2.60%	0.7%	30.0%
	5	2.60%	2.6%	30.0%
	6	2.60%	5.2%	30.0%
10	7	3.99%	10.1%	30.0%
	8	6.08%	6.1%	30.0%
	9	6.08%	13.9%	30.0%
	10	7.99%	4.0%	30.0%
	11	8.68%	5.2%	30.0%
15	12	8.68%	17.4%	30.0%
	13	9.03%	4.0%	30.0%
	14	9.03%	8.0%	30.0%
	15	1.30%	0.0%	40.0%
	16	1.30%	1.3%	40.0%
20	17	1.30%	4.6%	40.0%
	18	1.30%	7.2%	40.0%
	19	1.30%	13.0%	40.0%
	20	1.95%	2.6%	40.0%
	21	1.95%	5.2%	40.0%
25	22	1.95%	7.8%	40.0%
	23	1.95%	10.4%	40.0%
	24	2.60%	2.6%	40.0%
	25	2.93%	2.6%	40.0%
	26	2.93%	5.2%	40.0%
30	27	2.93%	7.8%	40.0%
	28	2.93%	10.4%	40.0%
	29	3.91%	1.3%	40.0%
	30	3.91%	3.9%	40.0%
	31	3.91%	6.5%	40.0%
35	32	3.91%	10.4%	40.0%
	33	4.60%	1.3%	40.0%
	34	4.60%	13.0%	40.0%
	35	5.20%	0.0%	40.0%
	36	5.99%	3.9%	40.0%
40	37	7.81%	0.0%	40.0%
	38	7.81%	1.3%	40.0%
	39	7.81%	7.2%	40.0%
	40	7.81%	13.0%	40.0%
	41	9.11%	2.6%	40.0%
45	42	7.81%	2.6%	50.0%
	43	2.60%	2.6%	50.0%
	44	0.66%	2.6%	50.0%
	45	2.60%	0.7%	50.0%
	46	2.60%	5.2%	50.0%
50	47	5.21%	2.6%	50.0%

-21-

TABLE II

	Ex.* No.	PSD (nM)	PSD (nM) Serum 120h	LD ₅₀ (ml/kg) (annexed)	Survival Total Exchange
5	1	487	554		
	2	409	1262		
	3	285	564		
	4	269	267		
10	5	221	230		
	6	235	242		
	7	205	223		
	8	270	245		
	9	280	276		
15	10	279	254		
	11	290	240		
	12	474	429		
	13	388	377		
	14	338	320		
20	15	363	460		
	16	290	436	90%	0%
	17	269	427		
	18	314	1163		
	19	435	1592	70%	33%
25	20	221	366		
	21	219	-		
	22	245	400		
	23	269	916		
	24	207	327	95%	83%
30	25	178	319		
	26	172			
	27	213	410		
	28	202	511		
	29	277	274		
35	30	220	247		
	31	259	255		
	32	327	511		
	33	239	206		
	34	655	705		
40	35	235			
	36	320	287		
	37	219			
	38	379	306	-	100%
	39	513	466		
45	40	595	838	0%	67%

* All emulsions (1-47) had a greater than three month shelf stability at room temperature as measured by particle size distribution analysis and visual inspection.

50

-22-

	<u>Ex. No.</u>	<u>PSD (nM)</u>	<u>PSD (nM) Serum 120h</u>	<u>LD₅₀ (ml/kg) (annexed)</u>	<u>Survival Total Exchange</u>
5	41	318	307		
	42	373	342		
	43	324	325		
	44	503	612		
	45	290	286		
10	46	428	427		
	47	300	324		

While we have hereinbefore described a number of embodiments of our invention, it should be apparent that other embodiments also exist within our invention. Therefore, it should be understood that the scope of this invention is to be defined by the claims rather than by the specific embodiments which have been presented hereinbefore by way of example.

-23-

We Claim:

1. An emulsion comprising a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly water soluble, and a surfactant, wherein the highly fluorinated organic compound is present in the emulsion in an amount between about 10% and about 60% by volume and the amounts of the surfactant and the oil are dependent on the volume percent of fluorocarbon and are defined by the volume depicted in Figure 1 and the surfaces that define that volume.
2. The emulsion according to claim 1, wherein the highly fluorinated organic compound is present in an amount between about 20% and about 60% by volume.
3. The emulsion according to claim 1, wherein the highly fluorinated organic compound is present in an amount between about 30% and about 55% by volume.
4. The emulsion according to claim 1, wherein the highly fluorinated organic compound is present in about 40% by volume.
5. The emulsion according to any one of claims 1 to 4, wherein the highly fluorinated organic compound is selected from the group consisting of perfluorodecalin and perfluorooctylbromide.
6. The emulsion according to claim 1, wherein the oil is a physiologically acceptable oil.

-24-

7. The emulsion according to claim 6, wherein the oil is selected from the group consisting of safflower oil and soybean oil.

8. The emulsion according to claim 1, wherein the surfactant is a physiologically acceptable surfactant.

9. The emulsion according to claim 8, wherein the surfactant is egg yolk lecithin.

10. The emulsion according to claim 1, further comprising at least one compound selected from the group consisting of isotonic agents, osmotic pressure controlling agents, serum extending agents and antioxidants.

11. A red blood cell substitute comprising an amount of an emulsion according to any one of claims 1 to 10, said amount being therapeutically effective for oxygen transport and delivery in humans.

12. A contrast agent for biological imaging comprising an amount of an emulsion according to any one of claims 1 to 10, said amount being clinically effective for imaging by modalities selected from the group consisting of nuclear magnetic resonance, x-ray, ultrasound and positron emission tomography.

13. A composition for enhancing cancer radiation treatment and chemotherapy comprising a therapeutically effective amount of an emulsion of any one of claims 1 to 10.

14. A composition for minimizing the adverse effects of coronary ballon angioplasty comprising a

-25-

therapeutically effective amount of an emulsion according to any one of claims 1 to 10.

15. A composition for preserving organs comprising a preserving effective amount of an emulsion according to any one of claims 1 to 10.

16. A composition for treating heart attack, stroke and vascular occlusions comprising a therapeutically effective amount of an emulsion according to any one of claims 1 to 10.

17. A method for sustaining the oxygen requirements of living organisms comprising the step of administering to a patient in a therapeutically acceptable manner an emulsion according to claim 11.

18. A method for enhancing cancer radiation and chemotherapy comprising the step of administering to a patient in a therapeutically acceptable manner an emulsion according to claims 13.

19. A method for minimizing the adverse effects of coronary balloon angioplasty by perfusion of an emulsion according to claim 14 through the central lumen of the catheter.

20. A method for preserving organs by perfusion of an emulsion according to claim 15.


21. A method for non-invasive imaging of internal organs and bloodflow using the emulsion of claim 12 in conjunction with magnetic resonance imaging, ultrasound, positron emission tomography or x-ray.

-26-

22. A method for treating heart attack, stroke and vascular occlusions comprising the step of administering to a patient in a therapeutically acceptable manner an emulsion according to claim 16.

$\frac{1}{1}$

FIG. 1



SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 89/01388

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁴ : A 61 K 31/02																	
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 5px;">Minimum Documentation Searched ⁷</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%;">Classification System</th> <th style="width: 75%;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">IPC⁴</td> <td style="padding: 5px;">A 61 K</td> </tr> </table> <div style="text-align: center; margin-top: 5px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁴	A 61 K											
Classification System	Classification Symbols																
IPC ⁴	A 61 K																
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%;">Category ¹⁰</th> <th style="width: 60%;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;"> EP, A, 0231091 (CHILDREN'S HOSPITAL MEDICAL CENTER et al.) 5 August 1987, see abstract; page 5, lines 18,19,33; page 6, lines 5,9,10,16; page 7, lines 6,9,15; page 8, lines 4-7,12-15, 28,32; claims cited in the application <div style="text-align: center;">--</div> </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-16,20</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;"> EP, A, 0080716 (THE GREEN CROSS CORP.) 8 June 1983, see page 5, line 4; page 7, line 11; page 8, lines 1-6 cited in the application <div style="text-align: center;">--</div> </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;"> US, A, 4252827 (KAZUMASA YOKOYAMA et al.) 24 February 1981, see abstract; claims cited in the application <div style="text-align: center;">--</div> </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;"> FR, A, 2246262 (THE GREEN CROSS CORP.) 2 May 1975, see claims cited in the application <div style="text-align: center;">--</div> </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	EP, A, 0231091 (CHILDREN'S HOSPITAL MEDICAL CENTER et al.) 5 August 1987, see abstract; page 5, lines 18,19,33; page 6, lines 5,9,10,16; page 7, lines 6,9,15; page 8, lines 4-7,12-15, 28,32; claims cited in the application <div style="text-align: center;">--</div>	1-16,20	A	EP, A, 0080716 (THE GREEN CROSS CORP.) 8 June 1983, see page 5, line 4; page 7, line 11; page 8, lines 1-6 cited in the application <div style="text-align: center;">--</div>	1	A	US, A, 4252827 (KAZUMASA YOKOYAMA et al.) 24 February 1981, see abstract; claims cited in the application <div style="text-align: center;">--</div>	1	A	FR, A, 2246262 (THE GREEN CROSS CORP.) 2 May 1975, see claims cited in the application <div style="text-align: center;">--</div>	1
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
X	EP, A, 0231091 (CHILDREN'S HOSPITAL MEDICAL CENTER et al.) 5 August 1987, see abstract; page 5, lines 18,19,33; page 6, lines 5,9,10,16; page 7, lines 6,9,15; page 8, lines 4-7,12-15, 28,32; claims cited in the application <div style="text-align: center;">--</div>	1-16,20															
A	EP, A, 0080716 (THE GREEN CROSS CORP.) 8 June 1983, see page 5, line 4; page 7, line 11; page 8, lines 1-6 cited in the application <div style="text-align: center;">--</div>	1															
A	US, A, 4252827 (KAZUMASA YOKOYAMA et al.) 24 February 1981, see abstract; claims cited in the application <div style="text-align: center;">--</div>	1															
A	FR, A, 2246262 (THE GREEN CROSS CORP.) 2 May 1975, see claims cited in the application <div style="text-align: center;">--</div>	1															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>																	
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center;">17th August 1989</div> </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center;">15 SEP. 1989</div> </td> </tr> <tr> <td style="width: 50%; padding: 5px;"> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="width: 50%; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;"> <div style="text-align: right; font-weight: bold; font-size: 1.2em;">T.K. WILLIS</div> </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center;">17th August 1989</div>	Date of Mailing of this International Search Report <div style="text-align: center;">15 SEP. 1989</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;"> <div style="text-align: right; font-weight: bold; font-size: 1.2em;">T.K. WILLIS</div> </div>											
Date of the Actual Completion of the International Search <div style="text-align: center;">17th August 1989</div>	Date of Mailing of this International Search Report <div style="text-align: center;">15 SEP. 1989</div>																
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;"> <div style="text-align: right; font-weight: bold; font-size: 1.2em;">T.K. WILLIS</div> </div>																

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers* because they relate to subject matter not required to be searched by this Authority, namely:

* 17-19, 21-22

See PCT Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods

2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 8901388

SA 28603

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 07/09/89
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0231091	05-08-87	AU-A- 6796987 JP-A- 62228010	30-07-87 06-10-87
EP-A- 0080716	08-06-83	JP-A- 58225013 JP-A- 58092658 CA-A- 1187882 US-A- 4591593 US-A- 4713459	27-12-83 02-06-83 28-05-85 27-05-86 15-12-87
US-A- 4252827	24-02-81	None	
FR-A- 2246262	02-05-75	JP-A- 50069219 AT-B- 333962 AU-B- 471724 AU-A- 6520074 CA-A- 1042345 CH-A- 598749 DE-A, B, C 2404564 GB-A- 1445925 NL-A- 7402664 SE-B- 403433 SE-A- 7400989 US-A- 3962439 US-A- 3993581	10-06-75 27-12-76 29-04-76 07-08-75 14-11-78 12-05-78 17-04-75 11-08-76 08-04-75 21-08-78 07-04-75 08-06-76 23-11-76